NCT06769165 EMDR Treatment of Conditioned Nausea and Vomiting in Cancer Survivors
| NCT ID | NCT06769165 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Medical Center Groningen |
| Condition | Cancer Survivors |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-07-02 |
| Primary Completion | 2026-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2025-07-02 with a primary completion date of 2026-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To explore the effectiveness of EMDR therapy treatment in reducing symptoms of chemotherapy-induced conditioned nausea and vomiting in (former) patients with cancer.
Eligibility Criteria
Inclusion Criteria: * Previously pathologically confirmed diagnosis of cancer * Previously treated with systemic cancer therapy * Persistent complaints (more than 2 months) of conditioned nausea and/or vomiting * Able to understand spoken and written Dutch * 18 years or older Exclusion Criteria: * Ongoing psychiatric treatment * EMDR therapy contraindications (dissociative disorders, personality disorders or severe somatic disorders (e.g. cardiac arrhythmias)) * Complex type 2 trauma * Known with recent conditions / non-anti-cancer medication which can elicit nausea (e.g. pregnancy or alcohol abuses)
Contact & Investigator
Jacco J de Haan, MD, PhD
PRINCIPAL INVESTIGATOR
University Medical Center Groningen
Frequently Asked Questions
Who can join the NCT06769165 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, studying Cancer Survivors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06769165 currently recruiting?
Yes, NCT06769165 is actively recruiting participants. Contact the research team at j.j.de.haan@umcg.nl for enrollment information.
Where is the NCT06769165 trial being conducted?
This trial is being conducted at Groningen, Netherlands.
Who is sponsoring the NCT06769165 clinical trial?
NCT06769165 is sponsored by University Medical Center Groningen. The principal investigator is Jacco J de Haan, MD, PhD at University Medical Center Groningen. The trial plans to enroll 20 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.